Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 96, Issue 3, 2016, Pages 547-555

  Tian, Xi ^a   Warner, Samuel B ^a   Wagner, Kyle T ^a   Caster, Joseph M ^a   Zhang, Tian ^b   Ohana, Patricia ^c   Gabizon, Alberto A ^c,d   Wang, Andrew Z ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Lipomedix Pharmaceuticals Ltd   (Israel)

^d SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MATERIALS; CHEMORADIOTHERAPY; DISEASES; DRUG PRODUCTS; MAMMALS; RADIATION; RADIATION EFFECTS; TOXICITY;

ANTI-TUMOR EFFICACY; CLINICAL INVESTIGATION; COLORECTAL CANCER; CONTROLLED RELEASE; LIPOSOMAL FORMULATION; METHODS AND MATERIALS; RADIO-SENSITIZATION; TRIGGERED RELEASE;

RADIOTHERAPY;

ANTINEOPLASTIC AGENT; FLUOROURACIL; LIPOSOME; MITOMYCIN; PRODRUG; PROMITIL; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; DELAYED RELEASE FORMULATION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CHEMORADIOTHERAPY; COLORECTAL CANCER; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG ACTIVATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG RELEASE; DRUG SCREENING; DRUG STABILITY; FEMALE; HAIR DISEASE; HAIR TOXICITY; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; ORAL MUCOSITIS; PRIORITY JOURNAL; RADIOSENSITIZATION; SINGLE DRUG DOSE; SKIN TOXICITY; THROMBOCYTE COUNT; TUMOR XENOGRAFT; ADMINISTRATION AND DOSAGE; ANIMAL; CELL SURVIVAL; COLORECTAL NEOPLASMS; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG EFFECTS; HT-29 CELL LINE; NUDE MOUSE; PATHOLOGY; PROCEDURES; RADIATION RESPONSE; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL SURVIVAL; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HT29 CELLS; HUMANS; LIPOSOMES; MICE; MICE, NUDE; MITOMYCIN; PRODRUGS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 84990849587     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2016.06.2457     Document Type: Article

References (19)

1. 1 Seiwert, T.Y., Salama, J.K., Vokes, E.E., The concurrent chemoradiation paradigm—general principles. Nat Clin Pract Oncol 4 (2007), 86–100.
2. 2 Budach, W., Paulsen, F., Welz, S., et al. Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma. Br J Cancer 86 (2002), 470–476.
3. 3 Volpe, A., Racioppi, M., D'Agostino, D., et al. Mitomycin C for the treatment of bladder cancer. Minerva Urol Nefrol 62 (2010), 133–144.
4. 4 Ajani, J.A., Winter, K.A., Gunderson, L.L., et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 299 (2008), 1914–1921.
5. 5 Gabizon, A., Amitay, Y., Tzemach, D., et al. Therapeutic efficacy of a lipid-based prodrug of mitomycin c in pegylated liposomes: Studies with human gastro-entero-pancreatic ectopic tumor models. J Control Release 160 (2012), 245–253.
6. 6 Golan, T., Grenader, T., Ohana, P., et al. Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. Cancer Med 4 (2015), 1472–1483.
7. 7 Powis, G., Kirkpatrick, D.L., Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol 7 (2007), 392–397.
8. 8 Maeda, H., Wu, J., Sawa, T., et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 65 (2000), 271–284.
9. 9 Tian, X., Lara, H., Wagner, K.T., et al. Improving DNA double-strand repair inhibitor ku55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery. Nanoscale 7 (2015), 20211–20219.
10. 10 Au, K.M., Min, Y., Tian, X., et al. Improving cancer chemoradiotherapy treatment by dual controlled release of wortmannin and docetaxel in polymeric nanoparticles. ACS Nano 9 (2015), 8976–8996.
11. 11 Wang, E.C., Min, Y., Palm, R.C., et al. Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors. Biomaterials 51 (2015), 208–215.
12. 12 Karve, S., Werner, M.E., Sukumar, R., et al. Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proc Natl Acad Sci USA 109 (2012), 8230–8235.
13. 13 Amitay, Y., Shmeeda, H., Patil, Y., et al. Pharmacologic studies of a prodrug of mitomycin C in pegylated liposomes (Promitil (®)): High stability in plasma and rapid thiolytic prodrug activation in tissues. Pharm Res 33 (2016), 686–700.
14. 14 Rockwell, S., Cytotoxicities of mitomycin C and X rays to aerobic and hypoxic cells in vitro. Int J Radiat Oncol Biol Phys 8 (1982), 1035–1039.
15. 15 Rockwell, S., Kennedy, K.A., Combination therapy with radiation and mitomycin C: Preliminary results with EMT6 tumor cells in vitro and in vivo. Int J Radiat Oncol Biol Phys 5 (1979), 1673–1676.
16. 16 Rauth, A.M., Mohindra, J.K., Tannock, I.F., Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo. Cancer Res 43 (1983), 4154–4158.
17. 17 Rockwell, S., Effects of mitomycin C alone and in combination with X-rays on EMT6 mouse mammary tumors in vivo. J Natl Cancer Inst 71 (1983), 765–771.
18. 18 von der Maase, H., Overgaard, J., Vaeth, M., Effect of cancer chemotherapeutic drugs on radiation-induced lung damage in mice. Radiother Oncol 5 (1986), 245–257.
19. 19 Spremulli, E.N., Leith, J.T., Bliven, S.F., et al. Response of a human colon adenocarcinoma (DLD-1) to X irradiation and mitomycin C in vivo. Int J Radiat Oncol Biol Phys 9 (1983), 1209–1212.